Company / SG&A Expense
Vericel SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$167.0M
FY2025
5-year range
$61.1M / $167.0M
FY2021-FY2025
Trend
+16.9%
vs FY2024
Sector context
#83 of 213
Health Care
What the data says
At $167M, Vericel's sg&a expense ranks #131 of 213 in the Health Care sector. SG&A Expense has increased for 9 consecutive years, from $14M in FY2016 to $167M in FY2025.
Based on SEC 10-K filings.
$167M in FY2025 with a 5-year CAGR of +27.8%.
Increased from $121M to $167M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +34.4%
- 5-Year CAGR
- +27.8%
- 10-Year CAGR
- -
Sector benchmark
#131 of 213 in Health CareTop 61% of 213This company $167.0M Sector average $722.3M
▼
-76.9% below sector average
Key checks
Key Insights
- Vericel's sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +27.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 16.9% year-over-year.
- Ranks #83 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $167.0M | +16.9% |
| FY2024 | $142.8M | +18.0% |
| FY2023 | $121.0M | +75.8% |
| FY2022 | $68.8M | +12.6% |
| FY2021 | $61.1M | +24.8% |
| FY2020 | $49.0M | +37.6% |
| FY2019 | $35.6M | +30.0% |
| FY2018 | $27.4M | +21.8% |
| FY2017 | $22.5M | +63.2% |
| FY2016 | $13.8M | +134.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026